Partnering
Academic & Institutional Collaborations
Collaborations with cutting- edge national and international academic experts to discover new potential targets and advance the development of immuno-therapeutics in different solid tumor cancers.
Collaborations with cutting- edge national and international academic experts to discover new potential targets and advance the development of immuno-therapeutics in different solid tumor cancers.
Institut Curie
One of the most renowned cancer research academic institutions in Europe.
Biomunex has co-invented the MAIT engager approach with Institut Curie’s scientists, including notably Dr. Amigorena, but also Dr. Olivier Lantz, who was at the origin of the discovery of MAIT cells more than 25 years ago. Biomunex detains now 100% rights on patent covering the MAIT engager approach.
The Montpellier Cancer Research Institute
The Montpellier Cancer Research Institute (IRCM, Institut de Recherche en Cancérologie de Montpellier; Inserm 1194, Montpellier, France), as part of a program funded by the French National Research Agency in collaboration with Dr. Thierry Chardès (IRCM), that has enabled the identification of a new bispecific antibody that is more effective than standard therapeutic options in the treatment of pancreatic cancer.
The Universitätsklinikum Schleswig-Holstein
The Universitätsklinikum Schleswig-Holstein (UKSH), one of the largest medical centers in Europe located in Kiel, Germany, where BIOMUNEX is collaborating with the teams of Professor Matthias Peipp, Director of the Department of Antibody-Based Immunotherapy, and Professor Daniela Wesch, Institute of immunology, for the evaluation of some of its lead drug candidates in immuno-oncology, including several of its MAIT engagers.